Hyperprogression Emerges in a Subset of Patients Treated With Immunotherapy
Results from a recent multicenter, retrospective analysis of 242 patients with advanced non–small cell lung cancer (NSCLC) found that 16% developed hyperprogression during anti–PD-1/PD-L1 treatment.
Source: OncLive